We provide you with 20 years of free, institutional-grade data for ANNX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANNX. Explore the full financial landscape of ANNX stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-05-13 | 1528115 | ANNX | 10-Q | Url |
| 2024-03-26 | 1528115 | ANNX | 10-K | Url |
| 2023-11-13 | 1528115 | ANNX | 10-Q | Url |
| 2023-08-07 | 1528115 | ANNX | 10-Q | Url |
| 2023-05-08 | 1528115 | ANNX | 10-Q | Url |
| 2023-03-06 | 1528115 | ANNX | 10-K | Url |
| 2022-11-03 | 1528115 | ANNX | 10-Q | Url |
| 2022-08-08 | 1528115 | ANNX | 10-Q | Url |
| 2022-05-09 | 1528115 | ANNX | 10-Q | Url |
| 2022-03-01 | 1528115 | ANNX | 10-K | Url |
| 2021-11-09 | 1528115 | ANNX | 10-Q | Url |
| 2021-08-16 | 1528115 | ANNX | 10-Q | Url |
| 2021-05-17 | 1528115 | ANNX | 10-Q | Url |
| 2021-03-25 | 1528115 | ANNX | 10-K | Url |
| 2020-11-16 | 1528115 | ANNX | 10-Q | Url |
| 2020-09-08 | 1528115 | ANNX | 10-Q | Url |
| 2020-07-02 | 1528115 | ANNX | S-1 | Url |
Annexon, Inc(NASDAQ:ANNX) 
Annexon, Inc., a clinical-stage biopharmaceutical company, engages in developing therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its products in pipelines are focused on antibody-mediated autoimmune and complement-mediated neurodegenerative disorders....
Website: http://www.annexonbio.com
Founded: 2011
Full Time Employees: 38
CEO: Douglas Love
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ANNX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.